Thomas Steyer’s ChemoCentryx, Inc. CCXI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-800,000
Closed -$41.3M 314
2022
Q3
$41.3M Buy
+800,000
New +$33.1M 0.23% 78
2022
Q1
Sell
-935,463
Closed -$34.1M 347
2021
Q4
$34.1M Buy
935,463
+549,463
+142% +$19.3M 0.17% 78
2021
Q3
$6.6M Buy
+386,000
New +$6.01M 0.03% 172
2020
Q1
Sell
-1,500,000
Closed -$59.3M 121
2019
Q4
$59.3M Sell
1,500,000
-513,396
-25% -$9.01M 0.4% 49
2019
Q3
$13.7M Buy
2,013,396
+13,396
+0.7% +$101K 0.1% 81
2019
Q2
$18.6M Buy
2,000,000
+500,000
+33% +$5.79M 0.12% 79
2019
Q1
$20.8M Buy
1,500,000
+50,000
+3% +$572K 0.16% 71
2018
Q4
$15.8M Buy
1,450,000
+300,000
+26% +$3.16M 0.12% 72
2018
Q3
$14.5M Hold
1,150,000
0.09% 77
2018
Q2
$15.1M Buy
1,150,000
+200,000
+21% +$2.39M 0.09% 66
2018
Q1
$12.9M Buy
+950,000
New +$9.8M 0.09% 70

Other funds holding CCXI

Thomas Steyer's CCXI Position: Q4 2022 in Review

Thomas Steyer sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 800,000 shares — an estimated $41.3M sold.

Thomas Steyer first reported a position in CCXI in Q1 2018 and held it in 11 quarters. The position peaked at $59.3M in Q4 2019. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.

  • Thomas Steyer reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
  • Thomas Steyer sold 800,000 ChemoCentryx, Inc. shares in Q4 2022, an estimated $41.3M.
  • Thomas Steyer first reported a position in ChemoCentryx, Inc. in Q1 2018 and held it in 11 quarters.
  • Thomas Steyer's ChemoCentryx, Inc. position peaked at $59.3M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.

Based on Farallon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.